vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above Fifty Day Moving Average – What’s Next?

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $36.23 and traded as high as $37.99. vTv Therapeutics shares last traded at $35.31, with a volume of 16,208 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. TD Cowen started coverage on shares of vTv Therapeutics in a research note on Monday, January 5th. They set a “buy” rating for the company. Roth Mkm started coverage on vTv Therapeutics in a report on Thursday, January 22nd. They issued a “buy” rating and a $58.00 target price on the stock. Wall Street Zen upgraded vTv Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $47.00 price objective (up from $36.00) on shares of vTv Therapeutics in a research report on Friday, December 19th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.25.

vTv Therapeutics Price Performance

The firm’s 50 day simple moving average is $36.23 and its 200-day simple moving average is $27.06. The company has a market cap of $139.12 million, a price-to-earnings ratio of -10.64 and a beta of 0.50.

Institutional Investors Weigh In On vTv Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its position in shares of vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after acquiring an additional 12,896 shares during the last quarter. 683 Capital Management LLC acquired a new stake in vTv Therapeutics during the 4th quarter worth $731,000. Goldman Sachs Group Inc. purchased a new position in vTv Therapeutics during the 4th quarter worth $221,000. Finally, Baker BROS. Advisors LP grew its position in vTv Therapeutics by 52.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after purchasing an additional 51,000 shares during the last quarter. Hedge funds and other institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.